PL1638589T3 - Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego - Google Patents
Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianegoInfo
- Publication number
- PL1638589T3 PL1638589T3 PL04752284T PL04752284T PL1638589T3 PL 1638589 T3 PL1638589 T3 PL 1638589T3 PL 04752284 T PL04752284 T PL 04752284T PL 04752284 T PL04752284 T PL 04752284T PL 1638589 T3 PL1638589 T3 PL 1638589T3
- Authority
- PL
- Poland
- Prior art keywords
- mitoxantrone
- treatment
- multiple sclerosis
- combination therapy
- glatiramer acetate
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 229960003776 glatiramer acetate Drugs 0.000 title 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 title 1
- 229960001156 mitoxantrone Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47064003P | 2003-05-14 | 2003-05-14 | |
| PCT/US2004/015225 WO2004103297A2 (en) | 2003-05-14 | 2004-05-14 | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| EP04752284.2A EP1638589B1 (en) | 2003-05-14 | 2004-05-14 | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1638589T3 true PL1638589T3 (pl) | 2014-10-31 |
Family
ID=33476729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04752284T PL1638589T3 (pl) | 2003-05-14 | 2004-05-14 | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7968511B2 (pl) |
| EP (1) | EP1638589B1 (pl) |
| CA (1) | CA2525771A1 (pl) |
| DK (1) | DK1638589T3 (pl) |
| ES (1) | ES2466390T3 (pl) |
| HR (1) | HRP20140524T1 (pl) |
| IL (1) | IL171956A (pl) |
| PL (1) | PL1638589T3 (pl) |
| PT (1) | PT1638589E (pl) |
| SI (1) | SI1638589T1 (pl) |
| WO (1) | WO2004103297A2 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| NZ533327A (en) * | 2001-12-04 | 2006-11-30 | Teva Pharma | Processes for the measurement of the potency of glatiramer acetate |
| CA2569098A1 (en) * | 2004-05-28 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis |
| ES2572811T3 (es) * | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
| EP1838326A4 (en) * | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
| US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| AU2006320162B2 (en) * | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
| JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
| US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
| WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
| RU2390334C1 (ru) * | 2008-12-17 | 2010-05-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" | Способ лечения рассеянного склероза |
| EA019998B9 (ru) | 2009-08-20 | 2016-01-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| PL2627669T3 (pl) | 2010-10-11 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| EP2765857A4 (en) | 2011-10-10 | 2015-12-09 | Teva Pharma | SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617319A (en) * | 1985-06-13 | 1986-10-14 | American Cyanamid Company | Method of treating multiple sclerosis |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
-
2004
- 2004-05-14 PL PL04752284T patent/PL1638589T3/pl unknown
- 2004-05-14 DK DK04752284.2T patent/DK1638589T3/da active
- 2004-05-14 CA CA002525771A patent/CA2525771A1/en not_active Abandoned
- 2004-05-14 US US10/556,454 patent/US7968511B2/en not_active Expired - Fee Related
- 2004-05-14 HR HRP20140524TT patent/HRP20140524T1/hr unknown
- 2004-05-14 PT PT47522842T patent/PT1638589E/pt unknown
- 2004-05-14 ES ES04752284.2T patent/ES2466390T3/es not_active Expired - Lifetime
- 2004-05-14 WO PCT/US2004/015225 patent/WO2004103297A2/en not_active Ceased
- 2004-05-14 EP EP04752284.2A patent/EP1638589B1/en not_active Expired - Lifetime
- 2004-05-14 SI SI200432163T patent/SI1638589T1/sl unknown
-
2005
- 2005-11-14 IL IL171956A patent/IL171956A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1638589A2 (en) | 2006-03-29 |
| HRP20140524T1 (hr) | 2014-12-19 |
| ES2466390T3 (es) | 2014-06-10 |
| IL171956A (en) | 2011-08-31 |
| PT1638589E (pt) | 2014-06-12 |
| SI1638589T1 (sl) | 2014-07-31 |
| US20070173442A1 (en) | 2007-07-26 |
| CA2525771A1 (en) | 2004-12-02 |
| EP1638589B1 (en) | 2014-03-26 |
| US7968511B2 (en) | 2011-06-28 |
| WO2004103297A3 (en) | 2005-03-17 |
| DK1638589T3 (da) | 2014-06-30 |
| WO2004103297A2 (en) | 2004-12-02 |
| IL171956A0 (en) | 2006-04-10 |
| EP1638589A4 (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL171956A0 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
| IL180992A0 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| IL184037A0 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
| IL163725A0 (en) | Administration of agents for the treatment of inflammation | |
| AU2003220317A8 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| AU2003239531A1 (en) | Protein cages for the delivery of medical imaging and therapy | |
| EP1638605A4 (en) | DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE | |
| AU2003300791A1 (en) | Combination therapy for the treatment of pain | |
| EP1575582A4 (en) | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME | |
| ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
| IL177845A0 (en) | Combination therapy with glatiramer acetate and riluzole | |
| GB0213869D0 (en) | The treatment of pain | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| TWI365187B (en) | 7-azaindoles and the use thereof as therapeutic agents | |
| IL164951A0 (en) | The treatment of pain with lfendropil | |
| IL179330A0 (en) | Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis | |
| AU2002344959A1 (en) | Use of fasl for the treatment of neurodegenerative diseases | |
| AU2003217432A1 (en) | Angiopoietin-1 in the treatment of disease | |
| AU2003235665A8 (en) | Diagnostic and therapeutic uses of topors | |
| AU2003209489A1 (en) | Medical use of captopril for the treatment and prophylaxis of cancer | |
| GB0325957D0 (en) | The treatment of pain | |
| SI1610785T1 (sl) | Farmacevtski kombiniran pripravek za zdravljenje spastiäśnosti in/ali boleäśine | |
| AU2003293714A1 (en) | Methods for the treatment of chronic pain and compositions therefor | |
| SI1613340T1 (sl) | Zdravljenje Aspergillus infekcij s timozinom alfa |